Marinus Pharmaceuticals (MRNS) USPTO patents

Utility

Ganaxolone for Use In Treatment of Status Epilepticus

25 Aug 22

This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid.

David CZEKAI, Maciej GASIOR, Lorianne MASUOKA, Julia TSAI, Joseph HULIHAN, Alex AIMETTI

Filed: 26 Apr 22

Utility

Ganaxolone for Use In Treating Genetic Epileptic Disorders

11 Aug 22

The disclosure provides a method of treating a mammal having a genetic epileptic disorder, comprising chronically administering a pharmaceutically acceptable pregnenolone neurosteroid to a mammal having a genetic epileptic disorder in an amount effective to reduce the seizure frequency in the mammal.

Lorianne K. Masuoka, Jaakko Lappalainen

Filed: 24 Mar 22

Utility

Ganaxolone for Use In Treatment of Status Epilepticus

30 Jun 22

This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid.

David CZEKAI, Maciej GASIOR, Lorianne MASUOKA, Julia TSAI, Joseph HULIHAN, Alex AIMETTI

Filed: 4 Aug 21

Utility

Ganaxolone for use in prophylaxis and treatment of postpartum depression

8 Mar 22

Uses of ganaxolone in prophylaxis and treatment of postpartum depression are described.

Alex Aimetti, Christopher Cashman, Lorianne Masuoka, Jaakko Lappalainen

Filed: 6 Dec 19

Utility

Ganaxolone for use in treatment of status epilepticus

7 Sep 21

This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid.

David Czekai, Maciej Gasior, Lorianne Masuoka, Julia Tsai, Joseph Hulihan, Alex Aimetti

Filed: 26 Feb 21

Utility

Method of treatment using nanoparticulate ganaxolone formulations

27 Jul 21

In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.

Kenneth Shaw, Mingbao Zhang

Filed: 2 Oct 18

Utility

Ganaxolone for Use In Treatment of Status Epilepticus

24 Jun 21

This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid.

David CZEKAI, Maciej GASIOR, Lorianne MASUOKA, Julia TSAI, Joseph HULIHAN, Alex AIMETTI

Filed: 26 Feb 21

Utility

Methods of treating certain depressive disorders and delirium tremens

11 May 21

The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient.

Christopher Cashman, Jaakko Lappalainen, David A. Czekai

Filed: 25 Mar 20

Utility

Injectable Neurosteroid Formulations Containing Nanoparticles

6 May 21

Mingbao Zhang, Raymond C. Glowaky, David Czekai

Filed: 13 Aug 20

Utility

Injectable neurosteroid formulations containing nanoparticles

21 Sep 20

Mingbao Zhang, Raymond C. Glowaky, David Czekai

Filed: 13 Oct 16

Utility

Methods of Treating Certain Depressive Disorders and Delirium Tremens

16 Sep 20

The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient.

Christopher Cashman, Jaakko Lappalainen, David A. Czekai

Filed: 24 Mar 20

Utility

Ganaxolone for Use In Prophylaxis and Treatment of Pospartum Depression

10 Jun 20

Uses of ganaxolone in prophylaxis and treatment of postpartum depression are described.

Alex Aimetti, Christopher Cashman, Lorianne Masuoka, Jaakko Lappalainen

Filed: 5 Dec 19

Utility

Methods of treating certain depressive disorders and delirium tremens

4 May 20

The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient.

Christopher Cashman, Jaakko Lappalainen, David A Czekai

Filed: 2 Oct 18

Utility

Method of Administering a Neurosteroid to Effect Electroencephalographic (Eeg) Burst Suppression

23 Oct 19

The disclosure provides a method of eliciting electroencephalographic burst suppression or electroencephalographic suppression in a patient. the method includes administering to the patient a formulation comprising neurosteroid nanoparticles having a D50 of less than 2 microns and a polymeric surface stabilizer chosen from hydroxyethyl starch, dextran, and povidone and 0.1 to 50 mg of the neurosteroid per 1 kg of the patient's body weight The neurosteroid may be administered intravenously, intramuscularly, subcutaneously, or orally.

Michael SAPORITO, Albena PATRONEVA, David CZEKAI

Filed: 12 Oct 17